Additionally, the 36-month beta value for EBS is 2.06. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EBS is 52.32M and currently, short sellers hold a 17.15% ratio of that float. The average trading volume of EBS on April 25, 2025 was 1.20M shares.
EBS) stock’s latest price update
Emergent Biosolutions Inc (NYSE: EBS)’s stock price has increased by 7.83 compared to its previous closing price of 4.98. However, the company has seen a 16.23% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-22 that GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025.
EBS’s Market Performance
EBS’s stock has risen by 16.23% in the past week, with a monthly drop of -2.36% and a quarterly drop of -53.22%. The volatility ratio for the week is 5.90% while the volatility levels for the last 30 days are 9.27% for Emergent Biosolutions Inc The simple moving average for the last 20 days is 14.47% for EBS stock, with a simple moving average of -37.08% for the last 200 days.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with H.C. Wainwright repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on December 30, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see EBS reach a price target of $16. The rating they have provided for EBS stocks is “Buy” according to the report published on August 22nd, 2024.
The Benchmark Company gave a rating of “Buy” to EBS, setting the target price at $5 in the report published on March 07th of the previous year.
EBS Trading at -8.94% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.44% of loss for the given period.
Volatility was left at 9.27%, however, over the last 30 days, the volatility rate increased by 5.90%, as shares surge +3.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.47% lower at present.
During the last 5 trading sessions, EBS rose by +16.23%, which changed the moving average for the period of 200-days by -33.95% in comparison to the 20-day moving average, which settled at $4.69. In addition, Emergent Biosolutions Inc saw -43.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from Fowler Neal Franklin, who sale 35,000 shares at the price of $5.83 back on Mar 12 ’25. After this action, Fowler Neal Franklin now owns 101,100 shares of Emergent Biosolutions Inc, valued at $204,050 using the latest closing price.
Zoon Kathryn C, the Director of Emergent Biosolutions Inc, sale 10,000 shares at $5.73 during a trade that took place back on Mar 12 ’25, which means that Zoon Kathryn C is holding 44,482 shares at $57,300 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.31 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.18. The total capital return value is set at -0.05. Equity return is now at value -33.67, with -11.80 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at 1.37. The interest coverage ratio of the stock is -0.91.
Currently, EBITDA for the company is 36.9 million with net debt to EBITDA at 14.58. When we switch over and look at the enterprise to sales, we see a ratio of 0.82. The receivables turnover for the company is 6.72for trailing twelve months and the total asset turnover is 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.69.
Conclusion
In conclusion, Emergent Biosolutions Inc (EBS) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
